-
FBXO25 assembles an active SCF1(FBXO25) complex with SKP1, CUL1, and Roc1/RBX1, and its best-validated endogenous substrate is the transcription factor ELK-1, which it ubiquitinates for proteasome-dependent degradation.
"Validated substrate: The transcription factor **ELK-1** is the clearest experimentally validated endogenous substrate. FBXO25 physically associates with ELK-1 and promotes ELK-1 ubiquitination and proteasome-dependent degradation in human cells."
-
By degrading ELK-1, FBXO25 suppresses mitogen-induced ELK-1 target genes c-fos and egr-1, linking it to regulation of mitogen-responsive transcription.
"FBXO25 overexpression suppresses induction of ELK-1 target genes **c-fos** and **egr-1** following mitogen stimulation (PMA), consistent with reduced ELK-1 activity due to decreased ELK-1 protein levels."
-
FBXO25 localizes to discrete nuclear puncta (FBXO25-associated nuclear domains, FANDs) that co-localize with the proteasome and ubiquitinated proteins, and whose integrity depends on actin polymerization and RNA polymerase I activity, suggesting a nuclear proteostasis compartment.
"FBXO25 is not merely diffuse in the nucleus; it localizes to discrete nuclear puncta termed **FBXO25-associated nuclear domains (FANDs)**. These FANDs are reported to co-localize with the **proteasome** and **ubiquitinated proteins**, suggesting FBXO25 participates in a nuclear proteostasis/ubiquitin signaling compartment."
-
In human umbilical-cord MSCs, FBXO25 promotes histone H2B K120 monoubiquitination (with downstream H3K4me3 and OSX/SP7 activation) during osteogenic differentiation, indicating a chromatin-linked role beyond classical substrate degradation.
"In human umbilical cord-derived MSCs (hUC-MSCs), He et al. report that FBXO25 promotes **H2B K120 monoubiquitination (H2BK120ub)**, which is associated with increased **H3K4 trimethylation (H3K4me3)** and transcriptional activation of the osteogenic transcription factor **OSX (osterix/SP7)**."